Chronic Inflammatory Articles & Analysis
38 news found
Nanoparticles caused a long-lasting activation of DOPr in endosomes, which provided sustained inhibition of nociceptor excitability and relief from inflammatory pain. Conversely, nanoparticles containing a DOPr antagonist abolished the sustained inhibitory effects of DADLE. Thus, DOPr in endosomes is an endogenous mechanism and a therapeutic target for relief from ...
Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted PRAC’s recommendation to add measures to minimise risk of serious side effects with JAK inhibitors for chronic inflammatory disorders. “JAK inhibitors ...
Gesynta Pharma AB today announces the decision to advance the development of its clinical-stage drug candidate GS-248 in endometriosis - a chronic inflammatory condition affecting approximately 10 percent of all women of reproductive age. ...
Further financial terms were not disclosed. Gout is a chronic, progressive inflammatory form of arthritis affecting more than nine million people in the United States that is caused by excess uric acid in the body and needs to be managed aggressively. ...
GS-248 has a unique mechanism of action with the potential to treat patients with chronic inflammatory diseases. This is accomplished through a potent and selective inhibition of the enzyme microsomal prostaglandin E synthase-1 (mPGES-1). ...
"We are developing several highly selective oral, small molecule PAD4 inhibitors, with the goal of bringing this novel mechanism to the clinic as potential therapeutics for tumor metastasis in colorectal and pancreatic cancers, patients with liver metastasis as well as for both acute and chronic autoimmune/inflammatory diseases.” These findings were only ...
Systemic sclerosis (also known as scleroderma) is a chronic, autoimmune disease that leads to serious damage to the microvessels. ...
THOUSAND OAKS, Calif., May 12, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Otezla® (apremilast) have partnered with pop icon and entrepreneur Lance Bass, for the Double Take campaign to empower people to take action when it comes to psoriatic arthritis. As a singer, dancer and entertainer, Bass understands the importance of staying in tune with your body. Through the campaign, he has created ...
With support from from his friends and family, he decided to see a doctor and was diagnosed with psoriatic arthritis – a chronic, inflammatory form of arthritis which can cause swelling, stiffness and pain in and around the joints that worsens over time. ...
They bring a combined experience of over 100 years in research and clinical care of people dealing with chronic pain and inflammatory conditions. Panag's development pipeline of pain relief products include topical, oral, and ocular delivery solutions for challenging molecules. ...
Systemic sclerosis (also known as scleroderma) is a chronic, autoimmune disease that affects, among other things, the body's smallest vessels, the microvasculature, and is associated with great medical needs due to the current lack of safe and effective medicines. ...
Aurealis Therapeutics, a synthetic biology company developing ground-breaking four-in-one cell and gene therapies, announced today the publication of the first study on its investigational product AUP-16, a four-in-one -combination therapy using live Lactococcus lactis expressing three human therapeutic proteins for the treatment of chronic non-healing wounds. This announcement ...
Décory occurs in parallel with the company successfully completing an exclusive license and collaboration agreement with XBiome, for the clinical development and commercialization of AUP-16, Aurealis investigational therapy for Diabetic Foot Ulcer (DFU), other chronic wounds, and inflammatory diseases, in greater China. Laurent brings to the company ...
About Siolta Therapeutics Siolta Therapeutics is a clinical-stage biopharmaceutical company developing novel microbiome-based targeted therapeutics for the prevention and treatment of inflammatory, chronic, and life-threatening diseases. STMC-103H, currently in Phase 1b/2 development in the US (NCT05003804), is designed to trigger tolerant immunological ...
Aurealis Therapeutics, a synthetic biology company developing groundbreaking four-in-one cell and gene therapies and Xbiome, an AI-based microbiome drug development company, today announced that the two companies have entered into an exclusive license and collaboration agreement for the clinical development and commercialization of Aurealis investigational Diabetic Foot Ulcer (DFU), other ...
GALWAY, Ireland–Neurent Medical, a company pioneering innovative treatments for chronic inflammatory sino-nasal diseases, today announced Food and Drug Administration (FDA) clearance of its proprietary NEUROMARK™ Rhinitis Neurolysis Therapy™ (RNT). The clearance gives clinicians access to an in-office treatment designed to create lesions to ...
About BiomX BiomX is a clinical-stage microbiome company developing both natural and engineered phage cocktails designed to target and destroy bacteria that affect the appearance of skin, as well as target bacteria in the treatment of chronic diseases, such as inflammatory bowel disease, primary sclerosing cholangitis, cystic fibrosis, atopic dermatitis and ...
ByBiomX
Further financial terms were not disclosed. Gout is a chronic, progressive inflammatory form of arthritis affecting more than nine million people in the United States that is caused by excess uric acid in the body and needs to be managed aggressively. ...
Founded in 2007, SetPoint is dedicated to developing technologies to treat patients with chronic autoimmune diseases. The company is pioneering a new treatment paradigm, using electrical pulses that activate the body’s innate “inflammatory reflex,” for rheumatoid arthritis (RA), Crohn’s disease and other chronic autoimmune ...
GALWAY, Ireland–(BUSINESS WIRE)–Neurent Medical, a company pioneering innovative treatments for chronic inflammatory sino-nasal diseases, today announced expansions of its leadership team. ...